Clinical Trials in Chicago

Showing 6381-6400 of 20,493 trials

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

NCT04890236

This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Duvelisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change a patient's T cells to make them more efficient and have a longer duration for manufacturing of CAR-T cells.

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Emory University4 participantsStarted Jan 2022

Atlanta, Georgia, United States • Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

Inhibition of Anaphylaxis by Ibrutinib

NCT03149315

This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulineia (WM). We propose to administer this approved drug to adults with food allergy to inhibit food allergy responses.

Food AllergyAnaphylaxis Food

Ann & Robert H Lurie Children's Hospital of Chicago6 participantsStarted Apr 2017

Chicago, Illinois, United States

COMPLETEDNA2.2 miles

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

NCT02844465

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Temporal Lobe Epilepsy

MedtronicNeuro167 participantsStarted Dec 2016

Newport Beach, California, United States • Palo Alto, California, United States • San Francisco, California, United States +20 more locations

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Inhibition of Anaphylaxis by Ibrutinib

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Find Trials by Condition in Chicago

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Child Development and Primary Care in Low Income Families

Saypha® VOLUME Lidocaine for Midface Augmentation

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

International EXPAND Heart Pivotal Trial

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Heart EXPAND Continued Access Protocol

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

Polyethylene Wear Particle Analysis of TKA

CLUSTER Trial for Outbreak Detection and Response

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Non-Complex Biliary Stones DSC vs ERC